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Abstract 
 
BACKGROUND: The goal of this study was to characterize the performance of 19F cardiac magnetic 
resonance (CMR) for the specific detection of inflammatory cells in a mouse model of myocarditis. 
Intravenously administered perfluorocarbons (PFC) are taken up by infiltrating inflammatory cells and can 
be detected by fluorine-19 (19F) CMR. 19F-labeled cells should therefore generate an exclusive signal at the 
inflamed regions within the myocardium. 
METHODS AND RESULTS: Experimental autoimmune myocarditis (EAM) was induced in BALB/c 
mice. Following intravenous injection of 2x200µl of a PFC on day 19 and 20 (n=9) after immunization, in 
vivo 19F-CMR was performed at the peak of myocardial inflammation (day 21). In 5 additional animals, PFC 
combined with fluorescein isothiocyanate (FITC) was administered for post-mortem immunofluorescence 
and flow cytometry analyses. Control experiments were performed in 9 animals.  
In vivo 19F-CMR detected myocardial inflammation in all EAM-positive animals. Its resolution was 
sufficient to identify even small inflammatory foci e.g. at the surface of the right ventricle. Post-mortem 
immunohistochemistry and flow cytometry confirmed the presence of PFC in macrophages, dendritic cells 
and granulocytes, but not in lymphocytes. The myocardial volume of elevated 19F signal (rs=0.96, p<0.001), 
the 19F SNR (rs=0.92, p<0.001) and the 
19F signal integral (rs=0.96, p<0.001) at day 21 correlated with the 
histological myocarditis severity score.  
CONCLUSIONS: In-vivo 19F-CMR was successfully used to specifically and robustly visualize the 
inflammation in EAM, and thus allowed for an unprecedented insight into the involvement of inflammatory 
cells in the disease process. 
 
Keywords: magnetic resonance imaging, perfluorocarbon, myocarditis, mouse 
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Text 
Introduction 
 Myocarditis is associated with a broad range of pathological immune processes in the heart1 and its 
clinical presentation can vary substantially. Acute myocarditis for example can present with arrhythmias, 
syncope, or even sudden cardiac death, but it can also progress slowly into a phenotype of inflammatory 
dilated cardiomyopathy2. Cardiac magnetic resonance (CMR) is now accepted as a sensitive method for the 
work-up of suspected myocarditis3, e.g. in the setting of acute or chronic heart failure4. In addition to the 
evaluation of cardiac function, CMR allows for tissue characterization by means of the late gadolinium 
enhancement (LGE) approach, which probes tissue viability, thereby detecting inflammatory lesions when 
accompanied by irreversible tissue damage5,6. CMR can also visualize tissue edema through T2-weighted 
imaging7 or more recently by T2 mapping
8. However, these CMR applications are not specific for a 
particular type of tissue injury, as necrosis and edema can also develop in the setting of ischemia, e.g. in 
acute coronary syndrome. In addition, these CMR methods do not provide information on the extent and 
timing of inflammatory cell infiltrations during the disease process. A non-invasive imaging strategy that 
detects inflammatory cells and which is not based on secondary tissue alterations (such as necrosis and/or 
edema) is therefore highly desirable for a more detailed characterization of myocarditis. Ideally, such a 
technique should exclusively detect inflammation and should be able to do so before alterations in tissue 
properties even occur. To this end, we investigated a novel CMR approach that is based on the ability of 
infiltrating inflammatory cells to phagocyte fluorine-containing particles and enables the non-invasive 
visualization of inflammatory lesions.  
 Since fluorine (19F) is virtually absent in animals and humans, 19F magnetic resonance imaging (MRI) 
offers the unique possibility to detect an injected substance that contains 19F without any background signal 
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and with 85% of the sensitivity of 1H MRI9. This theoretically results in a very high contrast-to-noise ratio 
(CNR) and a high specificity of the signal, as any 19F signal detected in the body can be unambiguously 
attributed to the injected 19F. As the signal received by an MR volume coil is directly proportional to the 
amount of 19F nuclei present in the tissue, the signal can be related to a reference of known 19F 
concentration, which renders this technique fully quantitative10. In this regard it differs from ‘indirect’ 
contrast agents that are based on relaxation time alterations (such as iron oxide or gadolinium), which often 
have a non-linear dose-signal response at higher concentrations11. Finally, the 19F signal can be fused with 
conventional 1H images for anatomical co-registration12. As demonstrated by several groups13, 19F MRI is 
able to detect macrophages after intravenous injection of PFC emulsions in several disease processes, such 
as pneumonia14, heterotopic acute cardiac allograft rejection in rat and in mouse models15,16, and in healing 
after myocardial infarction in mice17.  
 The goal of the present study was therefore to characterize the performance of 19F-CMR for the specific 
detection of inflammatory cells in a mouse model of CD4+ T-cell-mediated autoimmune myocarditis 
(EAM)18. EAM tends to progress into an inflammatory dilated cardiomyopathy (iDCM) phenotype along 
with development of increased interstitial fibrosis. In the EAM model quantifiable stages of acute 
myocarditis and iDCM can be distinguished19. EAM thus appears to be an ideal model to test the hypothesis 
that 19F-CMR is able to detect the inflammatory cells recruited to the myocardium of EAM mice both non-
invasively and quantitatively. In the setting of an inflammatory process, currently available MR methods 
allow for the measurement of necrosis, edema, fibrosis, and alterations of regional or global function. The 
proposed 19F-based CMR approach may provide complementary information related to the disease process 
itself, i.e. the amount and timing of myocardial infiltration by inflammatory cells, which could advance our 
understanding of the inflammatory disease process and may also enable an early detection of the disease. 
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Methods 
Experimental Autoimmune Myocarditis Model 
 All animal experiments performed in this study were approved by the local and institutional animal 
ethics committee. A total of 23 male BALB/c mice (29.4±3.2g) entered the study (Figure 1). To induce 
experimental autoimmune myocarditis (EAM), 17 mice were injected subcutaneously with 150µg of 
αMyHC peptide (Ac-RSLKLMATLFSTYASADR-OH; Caslo, Lyngby, Denmark) emulsified 1:1 with 
Complete Freund's Adjuvant (CFA, Difco, Franklin Lakes, NJ) on days 0 and 7, as previously described20. In 
the EAM model, immunization results in acute myocarditis that peaks approximately 21 days after 
immunization. Inflammation resolves slowly thereafter, while the number of cardiac fibroblasts 
progressively increases on follow-up21. Six mice were sham-immunized with saline/CFA and served as 
controls.  
In vivo Inflammatory-Cell Labeling 
 The main 19F in-vivo cellular labeling agent used in this study in 9 EAM mice was an emulsion of a 
linear polymer PFC (V-Sense 1000H, Celsense, Pittsburgh, PA, USA) that contains 1.67×1024 19F atoms per 
liter. Furthermore, 5 additional EAM mice were injected with a dual-labeled PFC that also contains FITC 
(fluorescein isothiocyanate) for post-mortem fluorescent microscopy and flow-cytometry analyses. This 
dual-labeling FITC-PFC is known to remain stable without dissociation of its components for over a week in 
cell cultures, while it is also characterized by a slightly decreased labeling efficiency versus the non-
fluorescent compound (unpublished data, provided by the manufacturer) and was thus not used in MR signal 
calculations. The PFC emulsion was administered through the tail vein at a dose of 200µL (6.8ml/kg body 
weight) on both day 19 and 20 after immunization (Figure 1).  Three EAM mice served as controls and were 
injected with saline instead of PFC before 19F-CMR. 
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1H and 19F-CMR 
 On day 21 after immunization, animals underwent isoflurane anesthesia. The animals were placed on 
top of a custom-designed 18mm-diameter quadrature surface coil tunable to both the 1H and 19F frequencies 
(400.2 and 376.6 MHz, respectively). The body temperature was monitored and kept constant at 37.0±0.5°C. 
A respiration-gated and ECG-triggered segmented k-space gradient echo sequence (repetition time 
TR=3.8ms, echo time TE=1.9ms, 4 signal averages, 128x128 matrix, 30x30mm2 field of view (FoV), slice 
thickness 2mm, total acquisition time ~5min) was used (9.4T spectrometer, Varian, Palo Alto, CA) to obtain 
three 1H short-axis images of the heart. At the anatomical location of the central slice, a prospectively gated 
gradient-echo cine imaging series (TR=10ms, TE=1.9ms, 14 frames, 4 signal averages, 128x128 matrix, 
slice thickness 1mm, total acquisition time ~5min) was also acquired. Next, at the location of the 3 1H short-
axis images, a turbo spin echo sequence (TR=500ms, TE=3.7ms, echo-train length 4, 240 signal averages, 
64x64 matrix, total acquisition time 32min) was used for the 19F-CMR acquisitions.   
 After the in-vivo CMR acquisitions, the animals were sacrificed with pentobarbital and the hearts were 
perfused with saline, excised and fixed in formalin for post-mortem analysis. To investigate whether the in-
vivo 19F signal was related to the proximity of the RF coil to the anterior wall of the heart, ex-vivo high-
resolution 1H- and 19F-CMR of the hearts of 7 mice (Figure 1A) placed with their apex closest to the RF coil 
was performed. A 3D gradient echo sequence (TR=7.0ms, TE=3.6ms, 256 signal averages, 128×128×64 
matrix, FoV 15×15×15mm3, acquisition time: 4h4min), which had better spatial coverage but inferior 
sensitivity per unit of time than the in-vivo sequence, was used. 
 All image analyses were performed on the unprocessed modulus images in Matlab (Mathworks, Natick, 
MA, USA). The total myocardial volume with elevated 19F signal (Volinflam) was determined as follows (for 
details, see Supplemental Figure 1): first, the heart and the liver were segmented on the anatomic 1H images. 
Next, the liver was segmented in the corresponding 19F images, while the 19F noise level was determined as 
the standard deviation of the 19F signal intensity of a large region outside the mouse body. Finally, the voxels 
of the 19F images that were in the region of the heart but not in the liver and had a 19F signal 7 times higher 
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than the noise were added up to Volinflam and their average signal-to-noise ratio (SNR) was calculated. This 
threshold for detection of 19F-positive pixels was applied to avoid pixel selection in minor motion-related 
ghosts and the isoflurane anesthetic that were consistently lower in signal than this threshold. The 19F signal 
integral was then calculated as the product of Volinflam and the SNR. To study the prevalent spatial 
distribution of the 19F signal in EAM6, the in-vivo 19F signal distribution of each animal was classified in 
analogy to the standard myocardial segmentation model22, but without the apical segment and with six 
additional segments covering the right ventricle. A segment was defined positive if ≥25% of pixels of the 
segment showed an elevated 19F signal. The LV area shortening fraction was calculated from end-diastolic 
and end-systolic 1H cine images acquired at the mid-ventricular level (Argus, Siemens Healthcare, Erlangen, 
Germany) as a rough estimate for global LV systolic function. 
A dilution series of the PFC in agar was created to ascertain the minimum 19F atomic concentration needed 
for its detection with the in-vivo pulse sequence at a given SNR=2.  
Histology, Immunohistochemistry and Immunofluorescence 
The inflammatory cell infiltrations of the excised hearts mentioned above were analyzed in paraffin sections 
(Figure 1). Adjacent heart sections were treated differently in order to determine 1) the myocarditis severity 
score with hematoxylin-eosin (HE), 2) the cell type in the inflammatory cell area by immunohistochemistry 
and 3) the presence of PFC-FITC in inflammatory cells by immunofluorescence. 
The myocarditis severity was scored as described previously19 on the HE-stained heart sections using a semi-
quantitative scale: 0 – no inflammatory infiltrates; 1 – small foci of inflammatory cells between myocytes; 2 
– larger foci of >100 inflammatory cells; 3 – >10% of a cross-section involved; 4 – >30% of a cross-section 
involved19. Correlations were calculated between this histological disease score and the 19F SNR, Volinflam, 
the signal integral, and the midventricular LV area shortening fraction. 
For immunohistochemistry, rabbit anti-mouse CD45 1:250 (BD Bioscience, Switzerland) and rat anti-mouse 
F4/80 1:150 (BMA Biomedicals, Switzerland) antibodies were used to detect inflammatory bone marrow-
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derived cells and macrophages, respectively. Diaminobenzidine (DAB) was used as the chromogen. For 
immunofluorescence, rat-anti-F4/80 1:100 (Abcam, Boston, MA, USA) and monoclonal rabbit-anti-FITC 
1:100 (Invitrogen, Switzerland) were used to detect macrophages and PFC-FITC, respectively. The 
fluorochrome-conjugated secondary antibodies used were Alexa 546 goat-anti-rat 1:600 and Alexa 488 
chicken-anti-rabbit, respectively (Invitrogen). Nuclei were detected with DAPI (Roche, Switzerland). 
Flow cytometry 
 Hearts from FITC-PFC-injected EAM mice (Figure 1C) were excised at day 21 after immunization, then 
perfused with cold PBS, dissected into small pieces and digested for 50min at 37C in collagenase 
blendzyme (Liberase; Roche, Switzerland). Single cell suspensions were obtained by straining through a 
70µm nylon mesh (BD Biosciences). Cells were washed twice with 50mL FACS buffer (1% FCS, 1 mM 
EDTA in phosphate buffered saline-PBS, all from Gibco, Switzerland) and incubated 30 minutes on ice with 
the appropriate combination of fluorochrome- or biotin-conjugated antibodies. The following antibodies 
were used: fluorochrome-conjugated antibodies: anti-CD45-PE, anti-CD11b-APC, anti-CD11c-APC, anti-
CD4-APC, anti-Gr-1-PE (all from BD Bioscience), biotin-conjugated antibodies: anti-F4/80 (Cedarlane, 
Burlington, ON, Canada), anti-CD45 (BD Bioscience). Streptavidin-APC (BD Bioscience) was used to 
detect biotin-conjugated antibodies. Cells were profiled with the FACS-Canto analyzer (BD Bioscience) and 
data were analyzed with FlowJo software (Tree Star, Ashland, OR). 
Statistical analyses 
All statistical analyses were made in SPSS Statistics 20.0 (IBM, Armonk, NY), The groups of EAM and 
control mice were compared with unpaired two-tailed Student’s t-tests. Correlations of the 19F-SNR, 
Volinflam, 
19F signal integral and LV area shortening with the disease severity score were calculated with 
Spearman’s ranked correlation.  p<0.05 was considered significant.  
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Results 
EAM was induced in 17 animals as confirmed in 11 animals by histology (Figure 1, experiments A,C,D). In 
the 3 animals used for flow cytometry, histology was not applicable, while in another 3 animals histology 
was not performed for technical/logistical reasons. No adverse effects were observed after PFC injections in 
any of the experiments.  
Detection of EAM by 19F-CMR 
 In-vivo CMR of PFC-injected mice with myocarditis demonstrated 19F signal in all 9 animals (see for 
example Figure 2, solid arrows). 19F-positive regions in the heart were well defined and showed a 
predilection of the sub-epicardial layers of the myocardium as illustrated in Figure 2C and 2D (inferior LV 
wall). Three-dimensional high-resolution ex-vivo CMR confirmed the predominantly subepicardial 
distribution of the 19F signal (n=10, from experiments A(n=7) and B(n=3)). An example is shown in Figure 
3. 
In the in vivo experiments, a 19F signal was furthermore observed in the liver (Figure 2, dotted arrows) and 
was attributed to PFC phagocytosed by Kuppfer cells23. This liver signal was also observed in the six sham-
immunized PFC-injected control animals without myocarditis (Figure 2F), while no 19F signal was detected 
in their hearts.  
 A diffuse low-intensity 19F signal that was ascribed to the anesthetic isoflurane was observed in the 
subcutaneous fat in most animals, but was usually removed by the processing threshold. The SNR of the 19F 
signal regions in the heart was 25±19 (range: 4 to 60), while Volinflam was 46±46mm
3 (range: 7 to 144mm3).  
 The distribution of the average 19F signal (n=11, experiments A,C) was located predominantly in the 
basal anterolateral part of the heart, while the 19F signal was completely absent in the inferior and 
inferoseptal segments (Figure 4).  
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The PFC dilution series showed an SNR~2 at a 19F concentration of ~10mM, which indicated that the post-
processing threshold cut off 19F concentrations lower than 35mM (7 times the standard deviation of the 
noise) or 15.4nmol/voxel. 
Co-localization of inflammatory cells and 19F signal in the inflamed myocardium 
 Immunohistochemistry confirmed the presence of CD45 and F4/80-positive inflammatory cells in the 
heart at locations where the 19F signal was observed by CMR (Figure 5). In the mice injected with the dual-
labeled emulsion, fluorescent microscopy demonstrated co-localization of the F4/80 marker (macrophage) 
and FITC (PFC) signal (Figure 6) and thus F4/80-positive macrophages were identified as a source of the 19F 
signal. 
Incorporation of PFC emulsion in different cells infiltrating the myocardium 
 To determine which cell types were able to incorporate the PFC-FITC emulsion in the inflammatory 
environment of the heart, flow cytometry analysis of FITC (which corresponded to PFC) was performed on 
non-myocyte single cell populations isolated from the myocardium of the EAM mice that were injected with 
the PFC-FITC emulsion. FITC was detected in CD45+/CD11b+ monocytes, CD45+/F4/80+ macrophages, 
CD45+/CD11c+ dendritic cells and CD45+/Gr-1+ granulocytes. While this EAM model is known to be 
mediated by CD4+ lymphocytes19, no FITC was detected in CD45+/CD4+ T-lymphocytes (Figure 7).  
Correlation of histological disease score and CMR parameters  
A significant correlation was found between the histological disease severity score and the SNR of the 
19F signal (rs=0.92, p<0.001) as well as Volinflam (rs=0.96, p<0.001) and the 
19F signal integral (rs=0.96, 
p<0.001), as demonstrated in Figure 8. In contrast, the midventricular LV area shortening fraction, which 
was used as an estimate of LV systolic function, did not correlate with the disease score (rs=-0.14, p=0.65). 
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The average midventricular LV area shortening fraction in the healthy animals was 72.2±5.5% (vs EAM 
mice: 66.2±8.3%, p=0.38).  
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Discussion 
In-vivo detection of inflammatory cell infiltration in EAM by 19F-CMR  
 To our knowledge, this pre-clinical study for the first time shows that in-vivo CMR is able to detect 
inflammatory infiltrations in a model of experimental autoimmune myocarditis. In the beating mouse heart, 
the spatial and temporal resolution of the 19F-CMR acquisitions was sufficiently high to detect immune cells 
in thin myocardial structures such as the surface of the left and right ventricular free walls as shown in 
Figure 2 and 5. In addition, the 19F signal was sufficiently specific to yield a close correlation with the 
histological disease severity. This 19F-CMR approach thus yields information on the myocardial 
inflammatory cell infiltration in myocarditis. Consequently, it expands our current armamentarium to 
characterize myocarditis by adding this information to that on necrosis, edema, fibrosis, and function that 
can already be obtained by conventional CMR techniques. 
 The EAM model shares several similarities with human inflammatory heart disease, such as relapses, 
the development of interstitial fibrosis, cardiac dilation and heart failure over time21. In the current in-vivo 
and particularly in the ex-vivo experiments, inflammatory infiltrates were predominantly observed in the 
subepicardial layers of the myocardium, which resembles the distribution of tissue damage in human viral 
myocarditis24. Similar to humans, the most prevalent location of inflammation in the mice with EAM was 
the base of the LV. However, in the animal model the predilection site for inflammation was found in the 
antero-lateral wall, while in humans the predilection site is typically the infero-lateral wall of the LV. 
Confirmation of infiltrating inflammatory cells as source of 19F signal in EAM 
 Since the PFC emulsion was injected intravenously to detect inflammation in the heart, it is crucial to 
determine into which cell types the PFC was incorporated in the in-vivo situation. While the immunostaining 
for CD45 and F4/80 was mainly detected in the subepicardial layers as was the 19F signal, this finding in 
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itself does not prove PFC incorporation into macrophages. Therefore, we used a PFC combined with FITC 
to co-localize its fluorescence within macrophages (Figure 5), which was not found in the controls. Finally, 
flow cytometry demonstrated incorporation of the PFC-FITC emulsion into F4/80+ macrophages, Gr-1+ 
granulocytes, CD11c+ dendritic cells, and CD11b+ monocytes. While the EAM model is mediated by CD4+ 
lymphocytes, no PFC-FITC incorporation was found in this cell population. Thus, these results support the 
notion that intravenously administered PFC in the EAM model yield 19F signals originating mainly from 
infiltrating inflammatory cells. In a model of LPS-induced pneumonia14 and in inflammation following 
cardiac and cerebral ischemia17, PFC was detected predominantly in the monocyte/macrophage  and 
dendritic cell fractions and to a lesser extent in neutrophils, while T-cells did not incorporate the PFC. Thus, 
these and other data15,25 are well in line with our current findings in the EAM model. 
Study Limitations 
 The use of a surface coil in this study yielded a high detection sensitivity for 19F, while it removed the 
option of direct fluorine quantification through comparison with an external reference phantom. For absolute 
quantification, a volume coil would be required in combination with a reference of known 19F concentration. 
Conversely, by using array coils or compressed sensing26 the received signal per unit of time could possibly 
be amplified several times compared to that obtained by the coil used in our experiments, thus allowing for 
shorter acquisition times and/or higher detection sensitivity. 
 Of note, no correlation was found between the midventricular LV area shortening fraction estimate and 
the disease score. This is not surprising, given that in the EAM model heart failure develops after the peak of 
acute inflammation, in most cases not earlier than 30 to 50 days after immunization. Nevertheless, as the 
area shortening fraction was calculated from a single mid-ventricular slice and not from the entire LV, we 
cannot entirely exclude that a correlation would exist if function of the entire LV had been measured. 
 Since PFCs are inert molecules, their elimination from the body is unlikely to cause toxicity concerns27. 
However, this aspect will require additional in-depth studies in the future. At the current stage, the minimum 
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required PFC dose for mocarditis detection by 19F-CMR is not yet known. Lower dosages than those used in 
this study may still be critically enabling for monitoring inflammatory cell infiltration and/or responsiveness 
to therapy by the PFC used in this study. Furthermore, for the method to be clinically useful, further studies 
are needed to demonstrate the ability to detect inflammation at earlier stages of myocarditis. In particular, 
the lack of PFC uptake by lymphocytes might decrease the sensitivity of this approach to detect early stages 
of myocarditis. 
Clinical perspective – Applications in humans 
 In the current in-vivo study, the SNR of the 19F positive heart regions was high (25±19) with a voxel size 
of 0.47x0.47x2mm3 acquired over 32min at 9.4T. Current voxel sizes in human studies to detect e.g. small 
necrotic lesions in myocarditis are in the order of 2x2x8mm3. Thus, with a 72-times larger voxel size in 
humans, a similar SNR for 19F could theoretically be obtained at 3T (instead of 9.4T) with a 7-minute 
acquisition. This rough estimate does not account for any improvements in pulse sequences and coil designs 
that may be exploited if such a 19F-based approach were further pursued on commercial human MRI 
scanners. Thus, transition of this 19F-CMR approach into the human setting appears to be in reach from a 
technical point of view. In addition, the PFC compounds are inert molecules and some of them have already 
passed safety trials in humans when used as potential plasma expanders27. When PFCs were used for in-vitro 
labeling experiments, no negative effects were found on cell viability and cell function of dendritic cells28 
and polymorphonuclear neutrophils29. In summary, these current and other preliminary results of 19F MRI 
applications for inflammation detection and the fact that the PFCs exhibit a high safety profile27-29, suggest a 
feasible and highly desirable transition of this 19F approach into a clinical application. From a biological 
point of view, future studies are needed to test whether human macrophages are able to incorporate PFC in-
vivo in sufficient quantities to allow for non-invasive detection by 19F-CMR. 
 In addition, conventional 1H anatomical images can easily be fused with the 19F images, which allows 
for an exact co-registration of the 19F signal with cardiac anatomy. Conventional 1H CMR can be applied in 
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the same session to assess myocardial global and regional function, cardiac remodeling, myocardial edema, 
perfusion, and necrosis.  
 Currently, the ability to detect myocarditis by conventional 1H CMR through secondary tissue 
alterations such as edema and necrosis is clinically highly valuable. However, the prospect of being able to 
non-invasively, quantitatively, and specifically visualize the early-stage recruitment of immune cells into the 
myocardium with a 19F-CMR approach could represent an important step towards a better understanding of 
the pathophysiology of myocarditis. It could also allow for early detection of the disease and it potentially 
opens opportunities for treatment monitoring of myocarditis. Longitudinal studies combining 1H- and 19F-
CMR could be used to assess the timing of inflammatory cell infiltration, development of edema and 
necrosis, alterations in function, and finally transition of myocarditis into various phenotypes such as e.g. 
dilated cardiomyopathy with local24 or interstitial30 fibrosis development. 
Conclusions 
 In this study, 19F-CMR was successfully applied in a mouse model of experimental autoimmune 
myocarditis to specifically and robustly visualize the inflammation process of myocarditis. This critically 
enabled an unprecedented insight into the involvement of inflammatory cells in the disease process. This 
approach can provide novel information on the magnitude and the timing of inflammatory cell infiltration in 
myocarditis and may add potentially valuable information complementary to that on necrosis, edema, 
fibrosis, and function obtained by conventional CMR methods. 
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Figure 1. Overview of the time scale of the different experimental procedures. Time advances from left 
to right and is indicated in days, while a number of animals X that und 
ergoes a certain procedure is given as n=X. A) For the principal investigation, n=9 mice were immunized to 
develop EAM and were subsequently injected with PFC. They were then sacrificed, after which n=7 excised 
mouse hearts received ex-vivo CMR, histology (‘histo’) and immunohistology (‘immuno’). B) n=6 mice 
served as healthy controls (disease grade 0). They were sham-immunized but received PFC injections. They 
were also used in the correlation calculations shown in Figure 8. C) n=5 mice received the dual-labeled 
FITC-PFC instead of PFC. n=2 of these mice were  used for co-localization of the PFC with macrophages 
through immunofluorescence (‘fluo’), while n=3 animals were used for flow cytometry to investigate which 
type of immune cells in the myocardium had phagocytized the PFC.  D) n=3 mice were immunized to induce 
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EAM but were injected with saline instead of PFC to assure that there were no 19F MR signals in the heart if 
no PFC was injected. 
 
Figure 2. In vivo 19F-CMR of myocarditis. (A) 1H CMR slice in the short-axis orientation at the base of the 
heart of a mouse with disease score 3; 1H CMR depicts the right and left ventricles (RV and LV) as well as 
the lung (Lu) and liver (Li). (B) 19F-CMR of the same anatomical location. Two regions with a 19F signal can 
be observed: a thin line at the level of the myocardium (solid arrow) and a larger region at the level of the 
liver (dotted arrow). The color coding for 19F signal intensity is given to the right (in arbitrary units). (C) 
Fusion of the 1H (A) and 19F images (B): the 19F signal co-localizes with the subepicardial layer of the LV 
anterior wall, the RV free wall (arrow) and the liver (dotted arrow). (D) A similar fused basal slice in an 
animal with disease score 4. Here, the 19F signal is spread over the majority of the ventricles with a 
subepicardial 19F signal in the inferior wall of the LV (arrow head).  (E) Animal with disease score 2 with a 
relatively small patch of 19F signal (arrow). (F) Healthy control, in which a 19F signal can only be observed 
in the liver (dotted arrow). 
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Figure 3. Three-dimensional ex vivo CMR of a mouse heart with myocarditis. (A) Anatomical 1H long-
axis MR image of the heart, sacrificed at day21 in an Eppendorf tube. (B) 19F MR image at the same 
anatomical location with the same resolution of 112×112×224µm3 as for the 1H image. (C) Fusion image 
demonstrating the 19F signal in the subepicardial layer of the LV. The blue lines indicate the location at 
which the orthogonal images in (D&E) are located. The pattern of the frames of the last three images (solid, 
dashed and dotted line) corresponds to the image orientations as shown by the corresponding cross-sectional 
line patterns. 
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Figure 4. Distribution of the average 19F signal over the standard myocardial segmentation. The 
concentric rings represent the basal, mid-ventricular and apical slices. A clear prevalence for the basal 
anterior and basal anterolateral segments can be observed. Interestingly, the 19F-CMR was also able to detect 
a significant 19F signal contribution from segments in the right ventricle. The percentage represents the 
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portion of the total of 19F-positive segments determined in n=11 animals (9 from experiment A and 2 from 
experiment C). 
 
Figure 5. Histological confirmation of inflammatory cell infiltration at the site of 19F-CMR signal. (A) 
Basic level short-axis in vivo fusion image of a mouse heart sacrificed at day 21 after immunization. (B) The 
equivalent slice from the 3D ex vivo 19F-CMR. The ventricular cavities have collapsed to a smaller volume, 
but 19F signal can still be observed at similar locations as in the in vivo image. (C) Overview of an HE-
stained heart section at the same anatomical level, where the right and left ventricles (RV and LV) can be 
clearly discerned. (D&E) Magnifications of the previous HE-stained heart section. Macrophages can be 
observed in a thin sub-epicardial layer of the RV myocardium (solid arrow). (F&G) CD45 staining in the 
adjacent heart section confirms the presence of inflammatory bone marrow-derived cells (solid arrow) in the 
sub-epicardial layer. (H&I) F4/80 staining in the adjacent heart section shows the presence of macrophages 
(solid arrow) at the same anatomical location. 
 
 Figure 6. Immunofluorescence staining of heart sections of EAM mice injected with the dual-mode 
(A-D) and regular (E-H) emulsion. (A) F4/80 immunostaining of macrophages infiltrates. (B) FITC 
immunostaining indicating the presence of dual-labeled PFC in the same heart section. (C) DAPI staining of 
nuclei. (D) Merging of (A-C), where the yellow coloration indicates overlap of F4/80 and FITC staining. (E-
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H)  Similar series of staining in an EAM mouse with the regular emulsion (i.e. without FITC). No signal is 
observed at the FITC frequency (F). 
 
Figure 7. Flow cytometry profiles of non-myocyte cell fractions isolated from EAM mouse hearts 
injected with the dual-mode PFC emulsion. Hearts were isolated at day 21 after immunization and 
injected with FITC-labeled PFC or PBS. Representative flow cytometry analysis of FITC-positive heart-
infiltrating cells gated on the CD45+ cells. The left panels depict CD45 and an immune-cell specific receptor 
expression (CD11b for monocytes, CD11c for dendritic cells, F4/80 for macrophages, Gr-1 for granulocytes 
and CD4 for T cells). Gating was performed on double positive populations (black squares with percentage 
of the total amount of cells), after which the FITC content of these populations is illustrated in the right 
panels. Histogram plots are shown with the isotype control in gray and the FITC-specific signal as a black 
line. 
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Figure 8. Correlations of the histological disease score and quantified CMR data. For these analyses, 
the EAM mice that received post-mortem histology and PFC(n=7) as well as the healthy controls that 
received PFC (n=6, overlapping points near the origin) were used. Linear fits were added to illustrate trends.  
(A) The 19F SNR shows a correlation (rs=0.92, p<0.001) with the histological severity of the disease. (B) A 
similar correlation was found for the volume of pixels that had an in vivo 19F MR signal 7 standard 
deviations above the noise (Volinflam) with the degree of disease severity (rs=0.96, p<0.001) and (C) with the 
19F signal integral (the product of Volinflam and the SNR; rs=0.96, p<0.001). (D) No correlation (rs=-0.14, 
p=0.65) was found between the LV area shortening fraction and the disease score. 
